Star Health: Board Approves Q2 FY27 Financial Results, Promoter Group Changes

Star Health and Allied Insurance Company Limited announced the outcomes of its Board of Directors meeting held on October 27, 2026. The Board approved the un-audited standalone financial results for the quarter and half year ended September 30, 2026, along with the limited review report. A key decision included the reclassification of Sthitaprajna Advisors LLP from the Promoter Group Category to the Public Shareholder Category.

Star Health Board Meeting Outcomes

The Board of Directors of Star Health and Allied Insurance Company Limited convened a meeting on Tuesday, October 27, 2026. During this meeting, the Board inter alia considered and approved several significant items.

Financial Results Approved

The primary approval was for the un-audited standalone financial results of the company for the quarter and half year ended September 30, 2026. These results were prepared in accordance with Regulation 30, 33, 51, and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accompanying these results is the Limited Review Report issued by the Joint Statutory Auditors, M/s. T R Chadha & Co LLP and M/s. MSKA & Associates LLP. Additionally, disclosures required under Regulation 52(4) and a declaration on the utilization of issue proceeds for non-convertible securities as per Regulation 52(7)(A) of SEBI LODR for the same period were also approved.

Promoter Group Reclassification

In a significant corporate action, the Board also approved the reclassification of Sthitaprajna Advisors LLP. This entity will be moved from the Promoter Group Category to the Public Shareholder Category.

Meeting Details

The Board meeting commenced at 11:30 A.M. (IST) and concluded at 06:30 P.M. (IST). In compliance with SEBI LODR Regulations 46 and 62, the aforesaid information has been hosted on the company’s website at www.starhealth.in.

Source: BSE

Previous Article

Piramal Pharma: Board Approves Q2 FY27 Unaudited Financial Results

Next Article

Piramal Pharma: Q2 FY27 Revenue Surges 28%, EBITDA Up 72%